This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

NICE guidance - warfarin (vitamin K antagonists) post myocardial infarction (MI)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

NICE have issued guidance as to the use of vitamin K antagonists post myocardial infarction (1):

  • high-intensity warfarin (INR >3) should not be considered as an alternative to aspirin in first-line treatment, for patients who have had an MI
  • for patients who have had an MI and are unable to tolerate either aspirin or clopidogrel
    • treatment with moderate-intensity warfarin (INR 2-3) should be considered for up to 4 years, and possibly longer
  • for patients who have had an acute MI, are intolerant to clopidogrel and have a low risk of bleeding, treatment with aspirin and moderate-intensity warfarin (INR 2-3) combined should be considered
  • for patients already being treated for another indication (mechanical valve, recurrent deep vein thrombosis, atrial fibrillation, left ventricular thrombus), warfarin should be continued
    • if a patient is being treated with moderate-intensity warfarin (INR 2-3) and who is at low risk of bleeding, then the addition of aspirin should be considered
  • combination treatment with warfarin and clopidogrel is not routinely recommended


  1. NICE (May 2007). Secondary prevention in primary and secondary care for patients following a myocardial infarction

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.


Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.